Jason Kolbert


Jason Kolbert Boosts Price Target for MannKind Corporation (MNKD) to $7; Here’s Why

Mannkind caught a price target boost from Maxim in the wake of a positive label revision for Afrezza.

What’s Holding Back MannKind Corporation’s (MNKD) Valuation? Maxim Sees a Company Poised for Growth

Analyst says MannKind’s Afrezza revenues can surpass debt, if investors can be patient for adoption.

Maxim Initiates Buy on Diagnostics Group Inc (IDXG); Sees 410% Upside for the Stock

Analyst Jason Kolbert of Maxim believes that Interpace Diagnostics Group Inc (NASDAQ:IDXG) has quite the upper hand over the leading market ruler Veracyte …

Maxim Sees Over 200% Upside for MannKind Corporation (MNKD)

  Shares of MannKind Corporation (NASDAQ:MNKD) are up nearly 3% in Friday trading session, as the inhaled insulin drug maker gets a vote …

AEterna Zentaris Inc. (USA) (AEZS) CEO’s Departure Raises Questions

AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) shares are tumbling nearly 7% in Monday’s trading session, following the news that CEO David Dodd is stepping …

Promising Future For Omeros Corporation (OMER) with Lead Drug Omidria?

Drug maker Omeros Corporation (NASDAQ:OMER) delivered solid results for its earnings report for the first quarter of the year 2017. In reaction, Maxim analyst Jason …

Here’s Why Maxim Slashed Price Target on Achillion Pharmaceuticals, Inc. (ACHN) Today

Maxim analyst Jason Kolbert slashes his price target on shares of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) to $5.

AEterna Zentaris Inc. (USA) (AEZS) Macrilen Is Back, Cheers Maxim

AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) shares are rising almost 8% today on the heels of indicating it intends to file a new drug …

Maxim Comments on Sophiris Bio Inc (SPHS) Ahead of Clinical Data Presentation at EU Urology Conference

In a research released Friday, Maxim analyst Jason Kolbert reiterated a Buy rating on shares of Sophiris Bio Inc (NASDAQ:SPHS), with a price target …